Slingshot members are tracking this event:

Axsome's (AXSM) AXS-05 Data Results from GEMINI Phase 3 Trial in Major Depressive Disorder

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Clinical Data   Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint)

  Statistically significant improvement versus placebo on all secondary endpoints at week 6, including remission (p<0.001), disease severity (p=0.002), functional impairment (p=0.002), and quality of life (p=0.011)

Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 16, 2019
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Gemini, Ax-05, Phase 3 Study, Major Depressive Disorder